Talking Ketamine Podcast

Ketamine offers rapid relief from severe depression and suicidal ideation, but its effects are often fleeting, creating a "fade" that leaves patients vulnerable. This Stanford study, published in the *American Journal of Psychiatry* (2026), tackles this challenge by exploring a novel pharmacological strategy: using low-dose buprenorphine to extend ketamine's benefits. Researchers disco...

Ketamine therapy, a beacon of hope for treatment-resistant depression, has been gaining traction, but its off-label use has raised concerns about standardization and safety. Imagine a powerful dissociative anesthetic, originally intended for battlefield use, being administered in strip mall clinics without proper monitoring or trained psychiatric support! The risk? A destabilized patient leaving t...

This episode dives into a 2026 case report revealing a surprising drug interaction: ketamine, used for pain management, induced the liver to accelerate the breakdown of critical immunosuppressant medications in a heart transplant recipient. Transplant patients rely on a delicate balance, where drugs like tacrolimus and sirolimus prevent organ rejection. However, these drugs are metabolized by spec...

Imagine standing in your bathroom, staring down at your current prescription bottles, terrified that your daily SSRI or SNRI might block the effects of your upcoming ketamine treatment. In Episode 62, we tackle "The Combination Question" by breaking down a highly practical 2026 brief report from Yale by Curran, Hardy, and colleagues. Looking at real-world data from 332 patients with Treatm...

Imagine knowing exactly what someone is feeling, but your brain forces you to second-guess yourself before you can even react. That is the reality of Treatment-Resistant Depression (TRD), which creates massive "cognitive friction" in social situations. Episode 61 breaks down a fascinating 2026 computational psychiatry study by Yoldas and colleagues that proves severe depression doesn't...

In Episode 60, we step outside the realms of mental health and anesthesia to explore a groundbreaking 2026 study by Korkmaz and colleagues that asks a shocking question: can ketamine fight cancer directly? We dive into an in vitro study focusing on HT-29 colorectal cancer cells, exploring the potential of repositioning this common anesthetic in the oncology world. Cancer cells are notoriously hard...

For decades, neurology has viewed adult brain damage as a relatively permanent state, offering mostly compensatory therapies to help patients adapt to their deficits. But Episode 59 explores a 2026 systematic review by Leon-Rojas and Sacks-Zimmerman that flips the script: could subanesthetic ketamine actually act as a powerful cognitive enhancer? We unpack the paradox of using a dissociative anest...

For decades, the clinical focus of treating Major Depressive Disorder has been on alleviating profound sadness. However, traditional monoaminergic antidepressants often fall short of treating anhedonia—the absolute absence of pleasure—and can even cause "emotional blunting" by placing an artificial ceiling on a patient's dopamine-driven joy. In Episode 58, we explore a landmark 2026 sy...

In Episode 57, we explore a groundbreaking 2026 study out of Hungary by Koncz and colleagues that challenges the foundation of modern psychiatry: do you actually have to "trip" to heal? For years, the pharmaceutical industry has searched for a sanitized, at-home version of ketamine, hoping that R-ketamine (arketamine) could deliver neuroplasticity without the intense psychotomimetic effect...

In Episode 56, we explore a fascinating 2026 pharmacokinetics study by Otto and colleagues that completely changes how we view oral ketamine for Treatment-Resistant Depression (TRD). When taken orally, ketamine hits a massive biological roadblock: the liver's "first-pass effect". The liver acts as an aggressive tollbooth, metabolizing almost all of the parent drug and transforming it i...

Bipolar depression creates an agonizing clinical trap: patients are paralyzed by severe lows, yet traditional antidepressants take weeks to work and carry the terrifying risk of an "affective switch"—triggering a manic episode or rapid cycling. In Episode 55, we explore a 2026 review by Queissner and colleagues showing how ketamine and esketamine rewrite the rules by bypassing serotonin an...

For decades, medicine has sold us the comforting "light switch" theory: under general anesthesia, we simply cease to exist for a few hours. But in Episode 54, we unpack Bruno Tonetto’s terrifying and fascinating 2026 paper, "Conscious Under Anesthesia," which argues that we have confused the silence of the body with the absence of the mind. We explore the "broken speaker" a...

In episode 53, we move out of the sterile lab and into the messy real world, examining a large naturalistic study of 224 patients from an Austin clinic. The paper by Kosted and colleagues compares standard "infusion-only" ketamine treatment against Ketamine-Assisted Therapy (KAT) to answer a costly question: is paying for a therapist to be in the room actually worth it? The average results...

For the podcast's one-year anniversary, we zoom out from single studies to examine a comprehensive masterpiece: the doctoral thesis of Jolien K.E. Veraart, representing nine years of research (2016–2026) at the University of Groningen. This document moves beyond the initial hype of "does it work?" to the mature, difficult questions of long-term maintenance and safety. We unpack the cri...

In the world of ketamine therapy, there is a distinct divide: the FDA-approved, insurance-covered "Gold Standard" (Esketamine/Spravato) versus the cheap, off-label generic (Racemic Ketamine). In this episode, we step into the ring to judge "The Nasal Spray Wars" using a groundbreaking 2026 meta-analysis by Bahji and colleagues published in the Journal of Affective Disorders. We bre...

For decades, we’ve imagined the synapse as a "chemical soup"—a messy place where one neuron sprays neurotransmitters at another, hoping for a connection. But in this milestone 50th episode, we use the lens of the groundbreaking book Nano-Organization of the Synapse to reveal the stunning reality: the synapse is actually a piece of high-precision Swiss watchmaking. We explore the revolution...

For decades, the "Monoamine Dogma" ruled psychiatry: the brain was a chemical soup, depression was a lack of serotonin, and the cure was simply "filling the tank." But there was always a glitch in the matrix—why did it take weeks for pills to work if the chemistry changed in hours? In this special 25th-anniversary episode, we review a retrospective paper from 2026 that traces the h...

Patients with diabetes often face a brutal "syndemic"—a tangled web of chronic illness, Relentless nerve pain (neuropathy), and severe depression, all fueled by a common biological enemy: metabolic inflammation and Advanced Glycation End-products (AGEs). In this episode, we explore why ketamine, with its rapid antidepressant and non-opioid painkilling properties, looks like the perfect &#3...

Clinicians measure success in symptom scores and receptor occupancy, but for patients with Treatment-Resistant Depression (TRD), success is defined by something far more personal: the return of connection, clarity, and "life." In this episode, we amplify the "Patient's Voice" through a comprehensive synthesis of qualitative studies by Walasek and colleagues. We trace the emotio...

For decades, the "trip" caused by ketamine—sensory detachment, time warping, and out-of-body experiences—was seen as a nuisance, a "bug" to be tolerated during anesthesia. But a groundbreaking 2025 review paper by Berra and colleagues asks a provocative question: What if dissociation is actually the point? In this episode, we dive into the "Science of Dissociation," explori...

For decades, ketamine has been viewed primarily through two lenses: a safe anesthetic or a rapid-acting antidepressant "reset button." But a new paper by Sophie Holland argues we may be missing half the picture. This episode challenges the binary view of ketamine by exploring two distinct therapeutic pathways defined essentially by dose: the Psychedelic and the Psycholytic. The Psychedelic...

Sickle Cell Disease (SCD) pain crises are the leading cause of hospitalization for affected children, causing excruciating vaso-occlusive episodes where misshapen blood cells block oxygen flow to tissues. For decades, the standard treatment has been high-dose opioids, but this often leads to tolerance, inadequate relief, and the dangerous paradox of opioid-induced hyperalgesia—where the treatment...

"Will this actually work for me?" It is the most critical question patients ask before investing time, money, and hope into ketamine therapy. In this episode, we analyze a massive body of research—including a systematic review of 112 studies and a real-world analysis of 77 patients —to find actionable predictors of success. The results are reassuringly broad: factors like age, sex, depress...

Surgery is a trauma that wrecks sleep, and for vulnerable patients, Post-Operative Sleep Disturbance (PSD) is a serious complication linked to delirium, increased pain, and slowed recovery. In this episode, we dive into a fascinating study that connects three seemingly unrelated dots: ketamine, sleep, and the oral microbiome. Researchers treated 130 high-risk surgical patients with a continuous lo...

Catatonia is often misunderstood as simple immobility, but it is a terrifying, life-threatening syndrome of stupor, mutism, and extreme negativism—a state where the brain is essentially "frozen." For decades, the standard protocol has been to step on the "brake pedal" using GABA-ergic drugs like lorazepam, followed by Electroconvulsive Therapy (ECT) if medication fails. But what ha...